SPG(SH:600529) Sou Hu Cai Jing·2025-10-27 21:26Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. reported a decline in revenue and net profit for the third quarter of 2025, indicating potential challenges in its operational performance and financial health [2][3][4]. Financial Performance Summary - The company's main revenue for Q3 2025 was 1.03 billion yuan, a decrease of 17.14% year-on-year [3][4]. - The net profit attributable to shareholders for Q3 2025 was 171.31 million yuan, down 30.15% compared to the same period last year [3][4]. - The net profit excluding non-recurring items for Q3 2025 was 160.88 million yuan, reflecting a 31.20% decline year-on-year [3][4]. - For the first three quarters of 2025, the total revenue was 3.40 billion yuan, a decrease of 11.10% year-on-year [3][12]. - The total profit for the first three quarters was 648.39 million yuan, down 25.66% year-on-year [3][12]. Cash Flow and Financial Ratios - The net cash flow from operating activities for the first three quarters was 510.96 million yuan, a decrease of 37.16% year-on-year [3][14]. - The company's debt ratio stood at 17.54% [2]. - The gross profit margin for Q3 2025 was 33.08% [2]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 79,503 [6]. - The largest shareholder, Shandong Luzhong Investment Co., Ltd., held 19.50% of the shares [6][7]. Market Activity - On October 27, 2025, the stock price closed at 21.29 yuan, with a trading volume of 57,200 shares and a turnover of 122 million yuan [1][2]. - The net inflow of main funds on the same day was 2.09 million yuan, accounting for 1.72% of the total turnover [2][4].